New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

SARASOTA, FLA., May 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury (TBI) and associated neuropsychiatric conditions.

Silo has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) titled "Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine." The invention applies to the use of ibogaine and related compounds for the treatment of TBI, post-traumatic stress disorder (PTSD) and associated conditions.

Silo's newest drug discovery initiative is in line with recently published clinical and neuroimaging findings demonstrating substantial improvements in patients with TBI following treatment with ibogaine-based protocols. Reported outcomes include significant reductions in depression and anxiety symptoms, as well as measurable structural brain changes, including increased cortical thickness, subcortical volume expansion, and reductions in predicted brain age following a single treatment.

In accordance with the Executive Order by President Trump announced on April 18, 2026, the FDA has granted Breakthrough Therapy designation to specific psychedelic drugs through a program designed to expedite the development and review of drugs intended to treat serious or life-threatening conditions. The Executive Order cites ibogaine's potential for conditions that persist after standard therapies are completed.